These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 24114694)

  • 41. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study.
    Chawla S; Blay JY; Rutkowski P; Le Cesne A; Reichardt P; Gelderblom H; Grimer RJ; Choy E; Skubitz K; Seeger L; Schuetze SM; Henshaw R; Dai T; Jandial D; Palmerini E
    Lancet Oncol; 2019 Dec; 20(12):1719-1729. PubMed ID: 31704134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Denosumab: Current Use in the Treatment of Primary Bone Tumors.
    Savvidou OD; Bolia IK; Chloros GD; Papanastasiou J; Koutsouradis P; Papagelopoulos PJ
    Orthopedics; 2017 Jul; 40(4):204-210. PubMed ID: 28732103
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Histomorphometric Analysis of Pre- and Post-Denosumab-Treated Giant Cell Tumor of Bone.
    Ud Din N; Umer M; Park YK
    Int J Surg Pathol; 2020 Dec; 28(8):859-867. PubMed ID: 32429739
    [No Abstract]   [Full Text] [Related]  

  • 44. Preoperative denosumab treatment with curettage may be a risk factor for recurrence of giant cell tumor of bone.
    Sano K; Suehara Y; Okubo T; Sasa K; Kurihara T; Akaike K; Kubota D; Torigoe T; Hasegawa N; Ishii M; Nakamura Y; Kim Y; Takagi T; Kaneko K; Hayashi T; Saito T
    J Orthop Surg (Hong Kong); 2020; 28(2):2309499020929786. PubMed ID: 32539628
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue.
    Lau YS; Sabokbar A; Gibbons CL; Giele H; Athanasou N
    Hum Pathol; 2005 Sep; 36(9):945-54. PubMed ID: 16153456
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Golden bullet-denosumab: early rapid response of metastatic giant cell tumor of the bone.
    Demirsoy U; Karadogan M; Selek Ö; Anik Y; Aksu G; Müezzinoglu B; Corapcioglu F
    J Pediatr Hematol Oncol; 2014 Mar; 36(2):156-8. PubMed ID: 24072245
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Giant cell tumour of bone.
    Thomas DM; Skubitz KM
    Curr Opin Oncol; 2009 Jul; 21(4):338-44. PubMed ID: 19444102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone.
    Lau CP; Huang L; Wong KC; Kumta SM
    Connect Tissue Res; 2013; 54(6):439-49. PubMed ID: 24060052
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
    Roitman PD; Jauk F; Farfalli GL; Albergo JI; Aponte-Tinao LA
    Hum Pathol; 2017 May; 63():89-97. PubMed ID: 28235628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Osteonecrosis of the Jaw and Rebound Hypercalcemia in Young People Treated With Denosumab for Giant Cell Tumor of Bone.
    Uday S; Gaston CL; Rogers L; Parry M; Joffe J; Pearson J; Sutton D; Grimer R; Högler W
    J Clin Endocrinol Metab; 2018 Feb; 103(2):596-603. PubMed ID: 29211870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Current concepts in the treatment of giant cell tumour of bone.
    van der Heijden L; Dijkstra S; van de Sande M; Gelderblom H
    Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RANK and RANKL expression in giant-cell tumour of bone.
    Roux S; Mariette X
    Lancet Oncol; 2010 Jun; 11(6):514. PubMed ID: 20522381
    [No Abstract]   [Full Text] [Related]  

  • 53. Denosumab for the management of bone disease in patients with solid tumors.
    Body JJ
    Expert Rev Anticancer Ther; 2012 Mar; 12(3):307-22. PubMed ID: 22192269
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors.
    Lipton A; Balakumaran A
    Expert Rev Clin Pharmacol; 2012 Jul; 5(4):359-71. PubMed ID: 22943116
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In Situ Hybridization Regardless of Histologic Pattern.
    Stagner AM; Sajed DP; Nielsen GP; Ebb DH; Faquin WC; Chebib I; Rivera MN; Ting DT; Resnick CM; Peacock ZS; Kaban LB; Deshpande V
    Am J Surg Pathol; 2019 Jun; 43(6):819-826. PubMed ID: 30998511
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of RANK-ligand inhibition in cancer: the story of denosumab.
    Castellano D; Sepulveda JM; García-Escobar I; Rodriguez-Antolín A; Sundlöv A; Cortes-Funes H
    Oncologist; 2011; 16(2):136-45. PubMed ID: 21285392
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL.
    Schieferdecker A; Voigt M; Riecken K; Braig F; Schinke T; Loges S; Bokemeyer C; Fehse B; Binder M
    Oncotarget; 2014 Aug; 5(16):6647-53. PubMed ID: 25138051
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protein Expression Profiling of Giant Cell Tumors of Bone Treated with Denosumab.
    Mukaihara K; Suehara Y; Kohsaka S; Akaike K; Tanabe Y; Kubota D; Ishii M; Fujimura T; Kazuno S; Okubo T; Takagi T; Yao T; Kaneko K; Saito T
    PLoS One; 2016; 11(2):e0148401. PubMed ID: 26863138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metastatic giant cell tumour of bone: a narrative review of management options and approaches.
    Xu R; Choong PFM
    ANZ J Surg; 2022 Apr; 92(4):691-696. PubMed ID: 35143093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Downregulation of miR-223 and miR-19a induces differentiation and promotes recruitment of osteoclast cells in giant-cell tumor of the bone via the Runx2/TWIST-RANK/RANKL pathway.
    Jiang ZY; Jiang JJ; Ma YS; Li HY; Shi W; Fu PL; Xu CF; Lu JZ; Fu D; Xu JG
    Biochem Biophys Res Commun; 2018 Nov; 505(4):1003-1009. PubMed ID: 30309658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.